Panel: The Rise of a Consumer-Like Pharma Market

Session details:

The popularity of obesity GLP-1s has coincided with an influx of direct-to-consumer drug sales channels, introducing a new dynamic into pharma’s traditional commercial playbook. Beyond GLP-1s, a growing number of drugs could make waves by bypassing traditional insurance channels and other pharmaceutical middlemen.